In an investigation, in vitro fludarabine resistance was observed in CLL samples with TP53 deletion, suggesting that in vitro drug sensitivity profiles can serve as a tool that refines individualized selection of drugs for treatment [428]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.